Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
出版年份 2022 全文链接
标题
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
作者
关键词
-
出版物
Blood Cancer Journal
Volume 12, Issue 6, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-06-29
DOI
10.1038/s41408-022-00695-5
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Targeting Nuclear Export Proteins in Multiple Myeloma Therapy
- (2022) Shambavi Richard et al. BIODRUGS
- Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β
- (2022) Leah M. Alabanza et al. Frontiers in Immunology
- The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma
- (2022) James A. Davis et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma
- (2021) Stefania Oliva et al. ANNALS OF HEMATOLOGY
- Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
- (2021) Philippe Moreau et al. LANCET ONCOLOGY
- Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma
- (2021) Matteo C. Da Vià et al. NATURE MEDICINE
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
- (2021) Mehmet Kemal Samur et al. Nature Communications
- Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN
- (2021) Peter M. Voorhees et al. Blood Advances
- Trends in survival from myeloma, 1990–2015: a competing risks analysis
- (2021) Mary Jane Sneyd et al. BMC CANCER
- Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
- (2021) Nizar J. Bahlis et al. JOURNAL OF CLINICAL ONCOLOGY
- Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- (2021) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
- (2021) Philippe Moreau et al. LANCET
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
- (2021) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods
- (2021) Jill Corre et al. LEUKEMIA
- Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
- (2021) Marc-Andrea Baertsch et al. Cancers
- Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
- (2021) Luciano J Costa et al. Blood Advances
- Chimeric antigen receptor T‐cells, bispecific antibodies, and antibody‐drug conjugates for multiple myeloma: An update
- (2021) Arjun Lakshman et al. AMERICAN JOURNAL OF HEMATOLOGY
- P-216: Daratumumab, Carfilzomib, Lenalidomide, & Dexamethasone for relapsed/refractory Myeloma with salvage autologous hematopoietic cell transplant: interim analysis of the multicenter 2nd chance protocol
- (2021) Gunjan Shah et al. Clinical Lymphoma Myeloma & Leukemia
- Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
- (2021) Luciano J. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Mortality trends in multiple myeloma after the introduction of novel therapies in the United States
- (2021) Moritz Binder et al. LEUKEMIA
- Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence
- (2021) Afroditi Katsarou et al. Science Translational Medicine
- Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma
- (2021) Mashhour Hosny et al. Journal of Clinical Medicine
- Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma
- (2021) Shih-Feng Cho et al. Cancers
- The safety of current and emerging therapies for multiple myeloma
- (2020) Omar Nadeem et al. Expert Opinion On Drug Safety
- Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
- (2020) Nizar J. Bahlis et al. LEUKEMIA
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
- (2020) Meletios Dimopoulos et al. LANCET
- Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
- (2020) Hartmut Goldschmidt et al. LEUKEMIA
- Salvage second transplantation in relapsed multiple myeloma
- (2020) Binod Dhakal et al. LEUKEMIA
- Association of morbid progression with overall survival among patients with multiple myeloma: Validation of the progression-free survival endpoint
- (2020) Aaron S. Rosenberg et al. Clinical Lymphoma Myeloma & Leukemia
- Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
- (2020) Shaji K. Kumar et al. Journal of the National Comprehensive Cancer Network
- Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
- (2020) Shaji K Kumar et al. LANCET ONCOLOGY
- Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial
- (2020) James Croft et al. LEUKEMIA
- Progression with Clinical Features is Associated with Worse Subsequent Survival in Multiple Myeloma
- (2019) Rajshekhar Chakraborty et al. AMERICAN JOURNAL OF HEMATOLOGY
- Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
- (2019) Sarah A. Holstein et al. Current Hematologic Malignancy Reports
- With equal access, African Americans have superior survival compared to Caucasians with Multiple Myeloma: a VA study
- (2019) Nathanael R Fillmore et al. BLOOD
- Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patients
- (2019) Ajay K. Nooka et al. CANCER
- Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, safety, and subgroups
- (2019) Robert Z. Orlowski et al. Clinical Lymphoma Myeloma & Leukemia
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
- (2019) Paul G Richardson et al. LANCET ONCOLOGY
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Second Autologous Hematopoietic Stem Cell Transplant as Salvage Therapy for Relapsed Multiple Myeloma: A Global Treatment Option for Eligible Patients
- (2018) Wilson I. Gonsalves et al. ACTA HAEMATOLOGICA
- Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival
- (2018) Eirini Katodritou et al. ANNALS OF HEMATOLOGY
- Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- (2018) David S. Siegel et al. JOURNAL OF CLINICAL ONCOLOGY
- Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
- (2018) Sara Bringhen et al. LEUKEMIA
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Salvage Second Autologous Hematopoietic Cell Transplantation in Relapsed Multiple Myeloma
- (2018) Patrick Alan Hagen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
- (2018) Laurent Garderet et al. BLOOD
- Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse
- (2018) Surbhi Sidana et al. LEUKEMIA
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
- (2018) Paul G. Richardson et al. Blood Cancer Journal
- Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study
- (2017) Evangelos Terpos et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Therapy for Relapsed Multiple Myeloma
- (2017) David Dingli et al. MAYO CLINIC PROCEEDINGS
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
- (2017) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma
- (2017) N Tandon et al. Blood Cancer Journal
- Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
- (2016) Rachid C. Baz et al. BLOOD
- Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
- (2016) K. M. Kortum et al. BLOOD
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
- (2016) Gordon Cook et al. Lancet Haematology
- American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
- (2015) Sergio Giralt et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
- (2015) J. J. Shah et al. BLOOD
- Guidelines for determination of the number of prior lines of therapy in multiple myeloma
- (2015) S. V. Rajkumar et al. BLOOD
- Innovation in the field of thrombocytopenias: achievements since the beginning of the century and promises for the future
- (2015) C. L. Balduini et al. HAEMATOLOGICA
- Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
- (2015) Brian A. Walker et al. JOURNAL OF CLINICAL ONCOLOGY
- Design Issues in Randomized Clinical Trials of Maintenance Therapies
- (2015) Boris Freidlin et al. JNCI-Journal of the National Cancer Institute
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Innovation in the field of thrombocytopenias: achievements since the beginning of the century and promises for the future
- (2015) C. L. Balduini et al. HAEMATOLOGICA
- Design Issues in Randomized Clinical Trials of Maintenance Therapies
- (2015) Boris Freidlin et al. JNCI-Journal of the National Cancer Institute
- Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
- (2013) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
- (2011) S. V. Rajkumar et al. BLOOD
- Approach to the treatment of multiple myeloma: a clash of philosophies
- (2011) S. V. Rajkumar et al. BLOOD
- Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma
- (2011) Shaji K. Kumar et al. CANCER
- Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma
- (2011) Valdas Peceliunas et al. LEUKEMIA & LYMPHOMA
- Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone
- (2010) Hong Chang et al. LEUKEMIA & LYMPHOMA
- Impact of early relapse after auto-SCT for multiple myeloma
- (2008) S Kumar et al. BONE MARROW TRANSPLANTATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search